Burns J W & Co. Inc. NY lowered its position in Pfizer, Inc. (NYSE:PFE) by 2.0% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 91,074 shares of the biopharmaceutical company’s stock after selling 1,887 shares during the quarter. Burns J W & Co. Inc. NY’s holdings in Pfizer were worth $3,059,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Sphera Funds Management LTD. bought a new position in Pfizer in the first quarter worth approximately $13,342,000. Searle & CO. lifted its holdings in Pfizer by 92.7% during the first quarter. Searle & CO. now owns 80,052 shares of the biopharmaceutical company’s stock worth $2,739,000 after buying an additional 38,500 shares during the period. E&G Advisors LP lifted its holdings in Pfizer by 6.8% during the first quarter. E&G Advisors LP now owns 62,258 shares of the biopharmaceutical company’s stock worth $2,130,000 after buying an additional 3,940 shares during the period. Insight 2811 Inc. lifted its holdings in Pfizer by 3.7% during the first quarter. Insight 2811 Inc. now owns 9,324 shares of the biopharmaceutical company’s stock worth $319,000 after buying an additional 329 shares during the period. Finally, Prentiss Smith & Co. Inc. lifted its holdings in Pfizer by 1.7% during the first quarter. Prentiss Smith & Co. Inc. now owns 14,948 shares of the biopharmaceutical company’s stock worth $511,000 after buying an additional 250 shares during the period. 69.00% of the stock is currently owned by institutional investors.

Shares of Pfizer, Inc. (PFE) traded down 0.28% during midday trading on Tuesday, reaching $35.45. The company’s stock had a trading volume of 5,545,972 shares. Pfizer, Inc. has a 52 week low of $29.83 and a 52 week high of $35.84. The stock has a market capitalization of $210.83 billion, a price-to-earnings ratio of 25.93 and a beta of 1.00. The company has a 50 day moving average of $33.71 and a 200-day moving average of $33.53.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 EPS for the quarter, beating analysts’ consensus estimates of $0.65 by $0.02. Pfizer had a net margin of 15.84% and a return on equity of 24.51%. The business had revenue of $12.90 billion during the quarter, compared to analysts’ expectations of $13.08 billion. During the same period in the prior year, the company earned $0.64 earnings per share. The business’s revenue was down 1.9% compared to the same quarter last year. Equities research analysts predict that Pfizer, Inc. will post $2.56 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which was paid on Friday, September 1st. Stockholders of record on Friday, August 4th were issued a $0.32 dividend. The ex-dividend date of this dividend was Wednesday, August 2nd. This represents a $1.28 dividend on an annualized basis and a dividend yield of 3.60%. Pfizer’s payout ratio is 94.12%.

A number of analysts have weighed in on the company. Sanford C. Bernstein set a $39.00 target price on Pfizer and gave the stock a “buy” rating in a report on Tuesday. Jefferies Group LLC set a $37.00 target price on Pfizer and gave the stock a “neutral” rating in a report on Monday. BMO Capital Markets restated a “buy” rating and set a $37.00 target price on shares of Pfizer in a report on Thursday, September 14th. Vetr lowered Pfizer from a “buy” rating to a “hold” rating and set a $35.71 target price for the company. in a report on Wednesday, September 13th. Finally, Berenberg Bank restated a “hold” rating and set a $36.00 target price (down previously from $39.00) on shares of Pfizer in a report on Tuesday, August 15th. Two research analysts have rated the stock with a sell rating, eleven have given a hold rating and ten have assigned a buy rating to the company. Pfizer currently has a consensus rating of “Hold” and a consensus price target of $37.83.

In other news, insider Sally Susman sold 38,230 shares of the company’s stock in a transaction dated Tuesday, September 12th. The shares were sold at an average price of $35.00, for a total value of $1,338,050.00. Following the completion of the sale, the insider now directly owns 145,649 shares of the company’s stock, valued at $5,097,715. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Ian C. Read sold 96,950 shares of the company’s stock in a transaction dated Friday, August 4th. The shares were sold at an average price of $34.00, for a total transaction of $3,296,300.00. The disclosure for this sale can be found here. Insiders sold 464,521 shares of company stock valued at $15,813,961 over the last ninety days. Corporate insiders own 0.06% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Pfizer, Inc. (PFE) Shares Sold by Burns J W & Co. Inc. NY” was originally reported by Daily Political and is owned by of Daily Political. If you are viewing this news story on another site, it was copied illegally and republished in violation of international trademark & copyright laws. The legal version of this news story can be read at https://www.dailypolitical.com/2017/09/19/pfizer-inc-pfe-shares-sold-by-burns-j-w-co-inc-ny.html.

About Pfizer

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.